News from arGEN-X A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 10, 2014, 01:00 ET arGEN-X and The Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenström's Macroglobulinemia

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of...


Jun 04, 2014, 03:56 ET ArGEN-X Enters Long-term Strategic Alliance With Shire Pharmaceuticals in Therapeutic Antibodies

  SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS  arGEN-X, a clinical-stage biopharmaceutical company...


May 29, 2014, 04:00 ET arGEN-X to Present Results of Phase 1 Study of ARGX-110, a Novel Anti-CD70 Antibody, in Patients With Advanced Cancer at ASCO

arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with...


May 28, 2014, 04:44 ET arGEN-X Announces Collaboration with Bayer to Discover and Develop Therapeutic Antibody Candidates

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of...


Apr 07, 2014, 04:00 ET arGEN-X Uses its Simple Antibody™ Platform to Identify Four 'Hotspots' on MET as Targets for its Therapeutic Antibody Program

New findings to be presented at the American Association for Cancer Research annual meeting  arGEN-X, a clinical stage human therapeutic...


Jan 13, 2014, 03:10 ET arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients

Study supported by a €3.5 million IWT grant from the Flemish Government arGEN-X, a clinical stage human therapeutic antibody company,...


Jan 13, 2014, 03:09 ET arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire

Enters into pilot research agreement with Boehringer Ingelheim arGEN-X, a clinical stage human therapeutic antibody company, announces the...


Dec 17, 2013, 03:00 ET ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study

Dose confirmed for Phase Ib safety and efficacy expansion study arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead...


Nov 04, 2013, 03:00 ET arGEN-X and de Duve Institute/UCL to Collaborate on Novel Immunomodulation Therapy in Cancer

arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement,...


Nov 04, 2013, 03:00 ET arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B

Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards...


Sep 19, 2013, 03:00 ET arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development Collaboration With Shire

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE...


Sep 17, 2013, 03:00 ET arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer

SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors arGEN-X, a clinical stage human monoclonal antibody...


Sep 12, 2013, 03:00 ET arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7

- Breakthrough data to be presented during the 'Discovery on Target' conference in Boston, MA, USA on September 23, 2013 arGEN-X, a...


Aug 06, 2013, 04:06 ET arGEN-X Grants Licenses to its NHance™ Antibody Half-Life Extension Technology

Meeting The Increasing Demand For Technologies That Enable Antibody Product Differentiation arGEN-X, a clinical stage biopharmaceutical company...


Apr 24, 2013, 07:26 ET arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodies arGEN-X, a...


Mar 25, 2013, 05:46 ET arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology

ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation arGEN-X, a clinical stage biopharmaceutical company specialized in...


Jan 07, 2013, 03:00 ET arGEN-X Initiates Phase Ib Study of ARGX-110 in Cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics,...


Jan 07, 2013, 03:00 ET arGEN-X Expands its Therapeutic Antibody Alliance With Shire

New Discovery Program Initiated Within 12 Months Of Collaboration Start arGEN-X, a biopharmaceutical company specialized in the discovery and...


Oct 25, 2012, 04:31 ET arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE...


Mar 19, 2012, 04:00 ET Argen-X Launches NHance™ Technology to Generate Better Human Antibody Therapies

ADDS A SECOND PROPRIETARY TECHNOLOGY TO LEVERAGE THE POWER OF THE SIMPLE ANTIBODY™ PLATFORM   arGEN-X announces today the launch of...


Mar 19, 2012, 04:00 ET arGEN-X Appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE...


Feb 29, 2012, 02:00 ET arGEN-X Enters Into a Therapeutic Antibody Alliance With Shire

Human Antibody Product Collaboration in Rare Diseases arGEN-X, a biopharmaceutical company focused on the discovery and development of human...


Feb 08, 2012, 04:00 ET ARGEN-X ADVANCES A THIRD THERAPEUTIC ANTIBODY PROGRAM INTO PRECLINICAL DEVELOPMENT

ARGX-111IS AN ANTI-C-MET ANTIBODY WITH BROAD APPLICABILITY IN CANCER arGEN-X, a biopharmaceutical company focused on the discovery and...


Dec 19, 2011, 04:00 ET arGEN-X is Awarded €1.3 Million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE...


Dec 01, 2011, 01:00 ET arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round

Funds will be Used to Progress Differentiated Therapeutic Antibody Programs into Clinical Development arGEN-X, a biopharmaceutical company...